Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib

Nuvation Bio Inc. (NYSE:NUVB) is among the 14 best booming stocks to buy right now. On January 12, the oncology company announced that it had entered into an exclusive licensing and collaboration agreement with Eisai Co. Ltd. to expand the global reach of its lung cancer pill.

Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai To Expand Global Reach of Taletrectinib

Taletrectinib is currently approved for use by patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the United States, China, and Japan. However, the agreement has now granted Eisai the rights to develop and commercialize the drug for the treatment of the disease in Europe, the Middle East, North Africa, India, and beyond in several other countries.

Nuvation Bio Inc. (NYSE:NUVB), in a press release, said it would retain full commercialization rights in the United States to maintain its focus on activities in the country. It will also lead global development and continue to focus on ongoing research studies.

In other news, on the same day, the company shared preliminary results for the fourth quarter and full year 2025, with IBTROZI’s (taletrectinib) net product revenue at $15.7 million for the fourth quarter, bringing the total to $24.7 million since its launch in June last year.

Following the results, H.C. Wainwright lowered its price target on the stock to $17 from $18, while maintaining a Buy rating. The firm noted that IBTROZI’s quarterly revenue largely came in line with expectations.

Wall Street analysts have a consensus Strong Buy rating on the stock, with an average share price target of $11.38, representing an upside of 76.16% as of the close on January 12.

Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company focused on the development of novel oncology therapies.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.